Guardian Pharmacy Services, Inc.(GRDN)— Stock Profile, AI Score & Financials
Healthcare · NYSE · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
Guardian Pharmacy Services, Inc. (GRDN) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores GRDN at 62.3/100 on a 32-signal composite quality model, placing it at rank #720 of 2,961 stocks — the top 25% of the AI-ranked universe. GRDN scores in the top quartile across balance sheet strength (94.3). Based on the latest XBRL financial filings (Q2 2026), Guardian Pharmacy Services, Inc. reports quarterly revenue of $351.8M, net income of $21.9M, an operating margin of 5.9%. Top institutional holders of GRDN by reported 13-F value include FMR, WELLINGTON MANAGEMENT GROUP LLP, BlackRock, based on the most recent SEC filings. GRDN trades on the NYSE exchange and files with the SEC under CIK 1802255. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GRDN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Guardian Pharmacy Services, Inc. directly from SEC EDGAR.
AI Quality Score
62.3/100
AI Rank
#720
Revenue
$351.8M
Net Income
$21.9M
Operating Margin
5.9%
GRDN key financials by period
Guardian Pharmacy Services, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$1.4B
$49.2M
5.0%
FY 2024
10-K
$1.2B
$-110.0M
-5.1%
Institutions holding GRDN
Institutional investors reporting a position in Guardian Pharmacy Services, Inc. on SEC Form 13F.
AI-extracted from the 10-Q filed 2026-08-06 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Revenue grew a modest 2.2% YoY to $351.8M as IRA-driven Medicare Part D price cuts offset acquisition and volume gains, while an $8.5M one-time legal settlement helped push net income to $22.1M.
Biggest Revenue Drivers
2025 Acquisitions+$13.3M
Incremental revenue contributed by pharmacy operations acquired during 2025
Organic revenue-$5.9M
Decreased primarily due to Inflation Reduction Act Medicare Part D price reductions, despite residents served rising to ~210,000 and prescriptions dispensed rising to 7.6 million
Biggest Revenue Drivers
Total revenue: $351.8M+2.2% YoY
2025 Acquisitions+$13.3M
Incremental revenue contributed by pharmacy operations acquired during 2025
Organic revenue-$5.9M
Decreased primarily due to Inflation Reduction Act Medicare Part D price reductions, despite residents served rising to ~210,000 and prescriptions dispensed rising to 7.6 million
Largest Expense Items
Cost of goods sold$271.7M-1.6% YoY
Decreased primarily due to product cost decreases from IRA drug pricing reforms, partly offset by $11.3M added from 2025 Acquisitions
Selling, general, and administrative expenses$59.4M+6.9% YoY
Increase driven by higher average employee headcount ($2.2M organic, $1.6M from 2025 Acquisitions)
Provision for income taxes$7.7M+104.0% YoY
Higher pre-tax income, partly offset by a lower effective tax rate (25.7% vs 29.9%) from a smaller IPO-related share-based compensation charge
Margins: Cost of goods sold fell from 80.2% to 77.2% of revenue on IRA-driven product cost decreases, but SG&A rose from 16.1% to 16.9% of revenue as expense growth outpaced revenue growth.
Watch Items from the Filing
Company expects IRA-related Medicare Part D price reductions to continue impacting year-over-year revenue and cost comparability throughout the remainder of 2026.
An $8.5 million one-time payor-reimbursement settlement (received April 21, 2026) drove most of the swing in Other expense (income), inflating net income to $22.1M versus $8.8M a year ago.
Residents served grew from 195,000 to 210,000 and prescriptions dispensed rose from 7.0M to 7.6M YoY, showing underlying volume growth despite pricing headwinds.
All revenue and long-lived assets are generated/held solely in the United States, with the company operating as a single reportable segment.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
